newsfilter
← Latest News
GlobeNewswire·

Organovo Highlights FXR314 Combination Therapy Potential and Plan

SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and inflammatory bowel disease